FDA decision: Anitocabtagene Autoleucel (anito-cel) by Gilead Sciences (in 2026)
FDA decision: Anitocabtagene Autoleucel (anito-cel) by Gilead Sciences (in 2026) Live odds across 1 market: a full approval or an accelerated approval at 89¢. R
Resolves Jan 1, 2027
- a full approval or an accelerated approval: Yes 89¢ (kalshi)
TRADING OPEN
8sFDA decision: Anitocabtagene Autoleucel (anito-cel) by Gilead Sciences (in 2026)
Resolves Jan 1, 2027
Total Volume
$2.8K
+$91 (24h)
Active Markets
1
Across 1 platforms
Frontrunner
89¢
a full approval or an accelerated approval
Biggest Mover 24h
-4¢
a full approval or an accelerated approval
Arb Opportunities
0
None detected
All Markets
| # | ||||||
|---|---|---|---|---|---|---|
| 1 | 89¢ | 89¢ | $2.8K+$91 24h | -4¢ | — |
Implied Probability
Consensus across platformsEvent Info
Whale Activity
Loading...